The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | CAR-T therapy as a replacement for triple combination therapy in CLL
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Barbara Eichhorst from the University Hospital Cologne, Cologne, Germany, discusses ongoing trials investigating CAR T-cell therapy in patients with chronic lymphocytic leukemia (CLL). Due to a defect in the patients’ T-cells, there was less success for in the beginning of CAR T-cell treatment. Recent results from trials however, show that when administering the BTK inhibitor ibrutinib beforehand, CAR T-cell retransfusion becomes more successful. Results of better tolerance of neurotoxicity and cytokine release syndrome show promising potential for CAR T-cells. Prof. Eichhorst talks about the future of treatment of CLL, highlighting the potential replacement of triple combination therapy, where a continuous treatment of obinutuzumab, ibrutinib, and venetoclax is used, with CAR T-cells therapy.
